Who are ABT-450/r/ABT-267's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glecaprevir and Pibrentasvir, Grazaoprevir/Elbasavir, Grazoprevir/Elbasvir, glecaprevir/pibrentasvir tablets, Post-transplant Grazoprevir and Elbasvir, Glecaprevir / Pibrentasvir Oral Tablet [Mavyret].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-450-r-abt-267.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ABT-450/r/ABT-267 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT-450/r/ABT-267 (ABT-450/r/ABT-267) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis C virus protease inhibitor and NS5A inhibitor combination. Area: Virology/Hepatology.

phase 3 Hepatitis C virus protease inhibitor and NS5A inhibitor combination HCV NS3/4A protease and NS5A protein Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

ABT-450/r/ABT-267 (ABT-450/r/ABT-267) — AbbVie. ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABT-450/r/ABT-267 TARGET	ABT-450/r/ABT-267	AbbVie	phase 3	Hepatitis C virus protease inhibitor and NS5A inhibitor combination	HCV NS3/4A protease and NS5A protein
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Grazoprevir/Elbasvir	Grazoprevir/Elbasvir	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis C virus protease inhibitor and NS5A inhibitor combination class)

AbbVie · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-450/r/ABT-267 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-450-r-abt-267. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab